Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein

Zeyan Pan(Shanghai Jiao Tong University), Zonghai Li(Renji Hospital), Zhimin Shi, Yi Wang(Renji Hospital), Ying Liu(Renji Hospital), Hua Jiang(Shanghai Jiao Tong University), Xiuqi Wu(Shanghai Jiao Tong University), Bizhi Shi(Shanghai Jiao Tong University), Min Yu(University of Maryland, Baltimore), Shengmeng Di(Shanghai Jiao Tong University), Hong Luo
Cancer Immunology Immunotherapy
August 4, 2018
Cited by 63


Related Papers